- Price
- $827.72
- Day
- -1.87%
- Mkt Cap
- $85.27B
- 52W Range
- $541.00 – $859.34
- Volume
- 535.2K
- Beta
- 0.24
Find a company by name or ticker and open its page
Snapshot of fundamentals, performance, and 5D scores.
Business fundamentals and company information
Recent price action and historical returns
How the business makes money, by product and geography
Five lenses on the stock. Click any card to dive deeper.
How to read these dimensions
The five dimensions are independent lenses on a company, not a single combined score. Read them together rather than in isolation: where one dimension scores differently from the others is often the most useful place to focus your own research. Each score is built from rules and weights you can adjust, so treat them as a transparent starting point for your analysis, not a recommendation to buy or sell.
Recent news headlines and analyst price-target moves
SEPTEMBER 14, 2026 REGN INVESTOR DEADLINE: Regeneron Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
San Diego, California--(Newsfile Corp. - September 5, 2026) - The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) common stock between August 1, 2025 and May 15, 2026, both dates inclusive (the "Class Period"), have until September 14, 2026 to seek appointment as lead plaintiff of the Regeneron class action lawsuit. Captioned Cheatham v.
B. Metzler seel. Sohn & Co. AG Grows Stock Position in Regeneron Pharmaceuticals, Inc. $REGN
B. Metzler seel. Sohn and Co. AG grew its holdings in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) by 37.5% during the undefined quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 4,472 shares of the biopharmaceutical company's stock after purchasing an
AlphaGrep UK Ltd Purchases Shares of 1,943 Regeneron Pharmaceuticals, Inc. $REGN
AlphaGrep UK Ltd acquired a new position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) in the undefined quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 1,943 shares of the biopharmaceutical company's stock, valued at approximately $1,212,000. Regeneron Pharmaceuticals comprises 0.4% of AlphaGrep
Robbins LLP Urges REGN Investors to Contact the Firm Before the September 14, 2026, Lead Plaintiff Deadline in the Class Action Against Regeneron Pharmaceuticals, Inc.
Robbins LLP is Investigating Allegations that Regeneron Therapeutics, Inc. (REGN) Misled Investors Regarding the Viability of its Phase III Fianlimab-Libta
SEPTEMBER 14, 2026 REGN INVESTOR DEADLINE: Regeneron Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit, Robbins Geller Rudman & Dowd LLP Announces
SAN DIEGO--(BUSINESS WIRE)---- $REGN #REGN--The case alleges Regeneron and its top executives made false and/or misleading statements to investors.